Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.96−0.16 (-3.88%)
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Atea Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Atea Pharmaceuticals's pe ratio was 13.2× on Jan 31, 2023, against 24.0× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 13.2× | −0.5 |
| 2022 | Dec 30, 2022 | 13.7× | −16.3 |
| 2021 | Dec 31, 2021 | 30.0× | – |
See a number that looks wrong?